<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894633</url>
  </required_header>
  <id_info>
    <org_study_id>CD-449-08</org_study_id>
    <nct_id>NCT01894633</nct_id>
  </id_info>
  <brief_title>Study of Whole-brain Irradiation With Chloroquine for Brain Metastases</brief_title>
  <acronym>CLQ</acronym>
  <official_title>Phase II Randomized, Double Blind, Placebo Controlled Study of Whole-brain Irradiation With Concomitant Daily-dose Chloroquine for Brain Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and purposes:Chloroquine (CLQ), an antimalarial drug, has a lysosomatrophic effect
      associate with increase the sensibility of Radiation through leakage of hidroliticenzimes,
      increase of apoptosis, autophagy mediated by lysosomalhidrolases and increase of oxidative
      stress &quot;in vitro&quot;. In this phase II study we evaluated the efficacy and safety as
      radiosensitizing of the Chloroquine plus concomitant 30 Gray (Gy) of Whole-brain irradiation
      (WBI)in patients with brain metastases (BM) from solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seventy-three eligible patients were randomized. Thirty-nine patients received WBI (30 Gy in
      10 fractions over 2 weeks) concomitant with 150 mg of CLQ for 4 weeks (the CLQ group).
      Thirty-four patients received the same schedule of WBI concomitant with a placebo for 4 weeks
      (the control arm). All the patients were evaluated for quality of life (QoL) using the EORTC
      QLQ-C30 questionnaire (Mexican version) before beginning radiotherapy and one month later.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Every third month after randomization until 24 months follow-up. Measured by brain MRI</time_frame>
    <description>Corresponding Complete plus Partial Response according with RECIST 1.1 Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Nervous System Progression Free Survival</measure>
    <time_frame>From time to progression to 24 months follow up</time_frame>
    <description>Clinical o radiological brain progression or death. Radiological Progression is measured by RECIST 1.1 Criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>The quality of life questionnaires were completed 1 day before radiotherapy began and 1 month later.</time_frame>
    <description>The 30-item EORTC Quality of Life (QoL) Questionnaire (EORTC QLQ-C30) version 3.0 (Mexican version) was used in this trial. The EORTC QLQ-C30 v3 consisted of five multi-item functional scales, three symptom scales, a global health status/QoL scale, and six single items</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Brain Metastasis</condition>
  <arm_group>
    <arm_group_label>Chloroquine, radiosensitizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the CLQ plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 Gy of whole-brain radiotherapy in 10 daily fractions and an oral matching placebo for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days</description>
    <arm_group_label>Chloroquine, radiosensitizer</arm_group_label>
    <other_name>Aralen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total brain radiotherapy</intervention_name>
    <description>30 Gy in 10 daily fractions from Monday to Friday</description>
    <arm_group_label>Chloroquine, radiosensitizer</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 80 years of age

          -  At leat one brain metastasis MRI

          -  KPS 70 or more

          -  RTOG-RPA I or II

          -  Basic Laboratory requirements

        Exclusion Criteria:

          -  Candidates for radiosurgery, neurosurgery

          -  Patients treated with radiotherapy before entered to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Arrieta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancerologia, Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Mexico DF</city>
        <state>DF</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2013</study_first_submitted>
  <study_first_submitted_qc>July 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancerologia de Mexico</investigator_affiliation>
    <investigator_full_name>Oscar Gerardo Arrieta Rodr√≠guez MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prophylactic Cranial Irradiation</keyword>
  <keyword>Metastasis</keyword>
  <keyword>Cloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

